Patent intelligence · US
US 9801852
Devices and methods for facilitating and controlling use of a medication
Devices and methods for facilitating and controlling use of a medication
Patent details — US 9801852
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 31, 2017
- Expiration
- Oct 26, 2037
- Applicant
- Jazz Pharmaceuticals, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/19, A61K31/191, A61K31/22
Quick answer
US 9801852 (Devices and methods for facilitating and controlling use of a medication) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Oct 31, 2017. Expires Oct 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/19, A61K31/191, A61K31/22, A61K31/365, A61K31/485
More from Jazz Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 9801852?
US 9801852 (Devices and methods for facilitating and controlling use of a medication) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Oct 31, 2017. Expires Oct 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9801852?
Jazz Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 9801852 expire?
Our index shows an expiration date of Oct 26, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.